IP Library Granted Patent US 8,282,913
Granted Patent B2
US 8,282,913 · App. 12/055,746 · Granted Oct 9, 2012

Ion binding polymers and uses thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,282,913
App. No.
12/055,746
Granted
Oct 9, 2012
Kind
B2
Abstract

The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising potassium binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of hyperkalemia, such as hyperkalemia caused by renal failure and/or the use of hyperkalemia causing drugs.

Claims (11)

1. A pharmaceutical composition comprising a potassium binding polymer and a pharmaceutically acceptable excipient, the potassium binding polymer being a crosslinked alpha-fluoroacrylic acid polymer comprising a Ca 2+ cationic counterion.

2. The pharmaceutical composition of claim 1 wherein the potassium binding polymer has a swelling ratio of less than 5.

3. The pharmaceutical composition of claim 1 wherein the potassium binding polymer has a swelling ratio of less than 3.

4. The pharmaceutical composition of claim 1 wherein the alpha-fluoroacrylic acid polymer is crosslinked with divinylbenzene, ethylene bisacrylamide, N,N′-bis(vinylsulfonylacetyl)ethylene diamine, 1,3-bis(vinylsulfonyl) 2-propanol, vinylsulfone, N,N′-methylenebisacrylamide polyvinyl ether, polyallylether, or a combination thereof.

5. The pharmaceutical composition of claim 1 wherein the alpha-fluoroacrylic acid polymer is crosslinked with divinyl benzene.

6. The pharmaceutical composition of claim 1 in the form of a chewable tablet.

7. The pharmaceutical composition of claim 1 wherein the potassium-binding polymer is in a bead form.

8. The pharmaceutical composition of claim 1 suitable for oral, intestinal, or rectal administration.

9. The pharmaceutical composition of claim 8 suitable for oral administration.

10. The pharmaceutical composition of claim 8 suitable for intestinal administration.

11. The pharmaceutical composition of claim 8 suitable for rectal administration.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 30, 2019
From: RELYPSA, INC.
To: VIFOR (INTERNATIONAL) LTD.
Reel/Frame 049899/0058 →
RELEASE OF SECURITY INTEREST Recorded Sep 2, 2016
From: CANTOR FITZGERALD SECURITIES
To: RELYPSA, INC.
Reel/Frame 039621/0142 →
SECURITY INTEREST Recorded Apr 27, 2016
From: RELYPSA, INC.
To: CANTOR FITZGERALD SECURITIES
Reel/Frame 038394/0034 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 31, 2013
From: CHARMOT, DOMINIQUE; CHANG, HAN-TING; LIU, MINGJUN; KLAERNER, GERRIT
To: ILYPSA, INC.
Reel/Frame 029733/0812 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 31, 2013
From: ILYPSA, INC.
To: RELYPSA, INC.
Reel/Frame 029733/0863 →